Caxton Associates LLP Gilead Sciences, Inc. Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 5,013 shares of GILD stock, worth $513,832. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,013Holding current value
$513,832% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,284Shares Held
996MCall Options Held
9.62MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$12.4 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$12 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.1 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$5.6 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$5.49 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $128B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...